BioInvest In The News

Opinion: Dozens of biotech companies are ‘free’ for investors’ taking (2-16-2016)
Top Picks 2016: Pharmaceuticals (1-28-2016)
Top Picks 2016: Anthera (1-15-2016)
2015's Top Performers (1-12-2016)
2015's Top Performers (12-30-2015)
Biotech Bets: A Mispriced Trio  (11-9-2015)
Company Updates
Intrexon Update (4-21-16)

Intrexon Update (4-21-16)

BIOINVEST BREAKING NEWS – Special Update – ACAD – Nuplazid Receives Positive 12-2 Vote From FDA Advisory Panel – Acadia’s Nuplazid was favorably reviewed by an FDA advisory panel today. The vote was 12-2 on efficacy, 11-3 on safety, and most importantly, 12-2 on the drug’s overall risk/benefit for Parkinson’s disease psychosis (PDP). Read more…

Acadia Update (3-29-16)

Acadia Update (3-29-16)

BIOINVEST BREAKING NEWS – Special Update – ACAD – Nuplazid Receives Positive 12-2 Vote From FDA Advisory Panel – Acadia’s Nuplazid was favorably reviewed by an FDA advisory panel today. The vote was 12-2 on efficacy, 11-3 on safety, and most importantly, 12-2 on the drug’s overall risk/benefit for Parkinson’s disease psychosis (PDP). Read more…

Ionis Update (3-23-16)

Ionis Update (3-23-16)

IONS Huge Winner as GILD Ruled to Infringe on IONS/Merck HCV Patent –Yesterday, a California District Court jury determined GILD’s blockbuster hepatitis C drugs Sovaldi and Harvoni infringe on two Merck/IONS patents. Read more…